# Clinical Trials Data KRAS - Document 5

# Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01190462

"eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n\* Diagnosis of advanced or metastatic colorectal cancer\n\* Progressive disease in the past 3 months\n\* Failed prior oxaliplatin-, fluorouracil (5-FU)-, and irinotecan-containing regimens AND have the presence of a k-ras mutation within codon 12, 13, or 61\n\nPATIENT CHARACTERISTICS:\n\n\* WHO performance status 0-2\n\* Adequate organ function\n\* No history of toxicity during statin use\n\* No other malignancy within the past 5 years\n\* No history of severe pulmonary disease\n\* No clinically relevant coronary artery disease\n\nPRIOR CONCURRENT THERAPY:\n\n\* See Disease Characteristics\n\* No prior epidermal growth factor receptor (EGFR)-targeting agents\n\* No concurrent verapamil or amiodarone",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
Yes, a patient with a KRAS mutation in codon 12, 13, or 61 \*would\* be eligible, provided they also meet all the other criteria listed. Specifically, the trial requires the presence of such a mutation.